CoChat

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

Open access
Chandran, Smita S., Ma, Jiaqi, Klatt, Martin G., Dündar, Friederike, Bandlamudi, Chaitanya, Razavi, Pedram, Wen, Hannah Y., Weigelt, Britta, Zumbo, Paul, Fu, Si Ning, Banks, Lauren B., Yi, Fei, Vercher, Enric, Etxeberria, Inaki, Bestman, Watchain D., Da Cruz Paula, Arnaud, Aricescu, Ilinca S., Drilon, Alexander, Betel, Doron, Scheinberg, David A., Baker, Brian M., Klebanoff, Christopher A. · 2022 · Nature Medicine
Cited by 130

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes derived from recurrently mutated driver genes. Here we describe a high-throughput platform combining single-cell transcriptomic and T cell receptor (TCR) sequencing to establish whether mutant PIK3CA, among the most frequently genomically altered driver oncogenes, generates an immunogenic public NeoAg. Using this strategy, we developed a panel of TCRs that recognize an endogenously processed neopeptide encompassing a common PIK3CA hotspot mutation restricted by the prevalent human leukocyte antigen (HLA)-A*03:01 allele. Mechanistically, immunogenicity to this public NeoAg arises from enhanced neopeptide/HLA complex stability caused by a preferred HLA anchor substitution. Structural studies indicated that the HLA-bound neopeptide presents a comparatively ‘featureless’ surface dominated by the peptide’s backbone. To bind this epitope with high specificity and affinity, we discovered that a lead TCR clinical candidate engages the neopeptide through an extended interface facilitated by an unusually long CDR3β loop. In patients with diverse malignancies, we observed NeoAg clonal conservation and spontaneous immunogenicity to the neoepitope. Finally, adoptive transfer of TCR-engineered T cells led to tumor regression in vivo in mice bearing PIK3CA-mutant tumors but not wild-type PIK3CA tumors. Together, these findings establish the immunogenicity and therapeutic potential of a mutant PIK3CA-derived public NeoAg.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01786-3

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 130

Metadata

Authors
Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. N., Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Da Cruz Paula, A., Aricescu, I. S., Drilon, A., Betel, D., Scheinberg, D. A., Baker, B. M., & Klebanoff, C. A.
Venue
Nature Medicine
Published
2022-04-28
Volume
28
Issue
5
Pages
946-957
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4224985744
Cited by
130
References
25
FWCI
8.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. https://app.cochat.ai/papers/10.1038/s41591-022-01786-3
The paper
Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. N., Banks, L. B., Yi, F., Vercher, E., Etxeberria, I., Bestman, W. D., Da Cruz Paula, A., Aricescu, I. S., Drilon, A., Betel, D., . . . Klebanoff, C. A. (2022). Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nature Medicine. https://doi.org/10.1038/s41591-022-01786-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.